Compare Illumina, Inc. (ILMN) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MasTec Inc — how do they compare? Illumina, Inc. trades at $189.78 (market cap $27.94B), while MasTec Inc trades at $348.21 (market cap $26.60B). The key difference: Illumina, Inc. and MasTec Inc are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | MTZ | |
|---|---|---|
Market Cap | $27.94B | $26.60B |
Sector | Health | Technology |
52-Week High | $194.33 | $437.51 |
52-Week Low | $91.00 | $172.51 |
Enterprise Value | $29.33B | $29.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MasTec (MTZ) trades at $336.61, up 2.13% with strong analyst support (88.9% buy ratings) and a consensus price target of $497.45. The stock shows a bearish technical signal despite recent earnings beats, with Q1 2026 EPS of $1.39 surpassing expectations. The company's $1.65 billion acquisition of Superior Group positions it to capitalize on AI-driven data center infrastructure demand, supported by a record $20.3 billion backlog. Valuation metrics include a P/E of 57.72 and ROE of 14.53%, indicating premium pricing but solid profitability.
Outlook remains positive due to infrastructure spending tailwinds and strategic acquisitions, though high valuation and integration risks from the Superior deal warrant caution. Revenue growth is projected to rise from $14.30 billion in 2025 to $15.30 billion in 2026, with net income margin improving to 2.94%. Key risks include execution challenges and macroeconomic sensitivity, but institutional bullishness suggests upside potential if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
